Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Shanghai Henlius Biotech, Inc.
  6. Summary
    2696   CNE100003N76

SHANGHAI HENLIUS BIOTECH, INC.

(2696)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Hong Kong Stock Exchange
09/13/2021 09/14/2021 09/15/2021 09/16/2021 09/17/2021 Date
27.1 27 26.2 25.1 25.25 Last
272500 169269 149900 231300 27300 Volume
-2.87% -0.37% -2.96% -4.20% +0.60% Change
Estimated financial data (e)
Sales 2021 1 577 M 244 M 244 M
Net income 2021 -720 M -111 M -111 M
Net Debt 2021 50,4 M 7,80 M 7,80 M
P/E ratio 2021 -18,1x
Yield 2021 -
Sales 2022 2 678 M 414 M 414 M
Net income 2022 -240 M -37,1 M -37,1 M
Net Debt 2022 1 086 M 168 M 168 M
P/E ratio 2022 -196x
Yield 2022 -
Capitalization 11 402 M 1 764 M 1 764 M
EV / Sales 2021 7,26x
EV / Sales 2022 4,66x
Nbr of Employees 1 972
Free-Float 20,1%
More Financials
Company
Shanghai Henlius Biotech Inc. is a China-based company principally involved in the research, development, production and sales of monoclonal antibody products. The CompanyÔÇÖs main products include rituximab injection HLX01 (Hanlikang), Herceptin (trastuzumab) biosimilar HLX02, Humira (adalimumab) biosimilar HLX03 and Avastin (bevacizumab) biosimilar HLX04, as well as bio-innovative drug candidates, including HLX06... 
Sector
Pharmaceuticals
Calendar
-
More about the company
Ratings of Shanghai Henlius Biotech, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about SHANGHAI HENLIUS BIOTECH, INC.
09/17Shanghai Henlius Biotech, Inc. Announces New Drug Application of Serplulimab ..
CI
09/17SHANGHAI HENLIUS BIOTECH : New Drug Application for Lung Cancer Treatment Accept..
MT
09/16Shanghai Henlius Biotech, Inc. Announces New Drug Application of Serplulimab ..
CI
09/16SHANGHAI HENLIUS BIOTECH : Wins Nod to Add Second Factory for Cancer Treatment i..
MT
08/24SHANGHAI HENLIUS BIOTECH : Henlius Biotech's Second Production Line for Cancer T..
MT
08/18Shanghai Henlius Biotech, Inc. Announces Earnings Results for the Six Months ..
CI
08/17Shanghai Henlius Biopharmaceutical Co., Ltd. Receives Approval for Supplement..
CI
08/05Shanghai Promega Biological Products Co., Ltd. and Shanghai Henlius Biotech, ..
CI
07/27SHANGHAI HENLIUS BIOTECH : Amended and restated articles of association
PU
07/20SHANGHAI HENLIUS BIOTECH : Henlius Biotech Doses First Patient in Phase I Study ..
MT
07/19Shanghai Henlius Biotech, Inc. Announces First Patient Has Been Dosed in Main..
CI
06/30Shanghai Henlius Biotech, Inc. Announces Change of Registered Address in Chin..
CI
06/07SHANGHAI HENLIUS BIOTECH : Henlius Biotech to Present Cancer Drug Trial Data at ..
MT
05/31SHANGHAI HENLIUS BIOTECH : Henlius Biotech Unit Wins FDA Nod to Start Clinical T..
MT
05/20SHANGHAI HENLIUS BIOTECH : Henlius Biotech Reports Clinical Trial Data for Arthr..
MT
More news
News in other languages on SHANGHAI HENLIUS BIOTECH, INC.

- No features available -

More news
Chart SHANGHAI HENLIUS BIOTECH, INC.
Duration : Period :
Shanghai Henlius Biotech, Inc. Technical Analysis Chart | 2696 | CNE100003N76 | MarketScreener
Technical analysis trends SHANGHAI HENLIUS BIOTECH, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 20,98 CNY
Average target price 50,22 CNY
Spread / Average Target 139%
EPS Revisions
Managers and Directors
Wen Jie Zhang President, CEO & Executive Director
Gino Li Chief Financial Officer & Vice President
Qi Yu Chen Chairman
Rong Li Feng Chairman-Supervisory Board
Wei Dong Jiang Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
SHANGHAI HENLIUS BIOTECH, INC.-46.22%1 764
CSL LIMITED9.25%102 521
WUXI BIOLOGICS (CAYMAN) INC.19.75%67 077
SAMSUNG BIOLOGICS CO.,LTD.12.95%52 329
BIOGEN INC.22.60%44 738
ALEXION PHARMACEUTICALS, INC.0.00%40 336